Eli Lilly

Lilly to invest $442 million in new biopharma facility in Ireland

Monday, February 27, 2012 03:18 PM

Eli Lilly is investing $442 million in a brand-new biopharmaceutical commercialization and manufacturing facility at its Kinsale campus in Cork, Ireland, according to Richard Bruton TD, minister for jobs, enterprise and innovation.

More... »

Sangart appoints three to leadership team

Friday, February 17, 2012 12:43 PM

Sangart, a privately held biopharmaceutical company focused on oxygen-therapeutic agents, has appointed three new members to its executive team.

More... »

Dendreon announces CEO and chairman succession plan

Wednesday, February 1, 2012 03:41 PM

Dendreon’s board of directors has elected John H. Johnson president and CEO, succeeding Mitchell H. Gold, M.D., who has served as both for nearly a decade.

More... »

ImmunoGen collaborates with Lilly

Tuesday, December 20, 2011 11:02 AM

ImmunoGen has entered into a collaboration agreement with Eli Lilly. Under this agreement, Lilly will pay an upfront fee of $20 million for rights to take a limited number of exclusive licenses to use ImmunoGen's maytansinoid Targeted Antibody Payload (TAP) technology with Lilly monoclonal antibodies to develop novel antibody-drug conjugate (ADC) anticancer therapeutics.

More... »

The CenterWatch Monthly, December 2011

Thursday, December 1, 2011 09:46 AM

Canada scrambles to reboot sagging clinical trials market

More... »

UCB inks strategic partnerships with Parexel, PRA

Monday, November 28, 2011 08:00 AM

The sponsor-CRO strategic partnerships just keep coming. 

More... »

Lilly awards IDRI $4 million in tuberculosis research funding

Tuesday, November 22, 2011 10:55 AM

The Infectious Disease Research Institute (IDRI) has been awarded more than $4 million in additional funding over the next four and a half years by Eli Lilly. The funding will support IDRI’s continued early phase drug discovery research, which focuses on the identification of effective new therapies in the fight against tuberculosis (TB), including multidrug-resistant TB (MDR-TB).

More... »

Kenexa partners with Eli Lilly

Thursday, November 17, 2011 03:08 PM

Kenexa, a global provider of business solutions for human resources, has reported that Eli Lilly will be using Kenexa’s global recruitment process outsourcing (RPO) services in some of the major markets where Lilly conducts business globally. The five year engagement represents Kenexa’s largest global RPO partnership, and also includes Kenexa’s onboarding, recruiting, assessment, and survey solutions and employment branding.  

More... »

Allena Pharmaceuticals secures $15 million in Series A financing

Wednesday, November 16, 2011 03:03 PM

Allena Pharmaceuticals, a company developing and commercializing innovative non-systemic oral protein therapeutics, has secured $15 million in Series A venture capital financing. Bessemer Venture Partners, Frazier Healthcare and Third Rock Ventures led the round. Proceeds from the financing will be used to accelerate the development of Allena's non-systemic protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions.

More... »

Quintiles fills in service offerings with acquisitions

Monday, November 7, 2011 08:00 AM

Quintiles has been on an acquisitions spree. 

More... »